Navigation Links
R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients
Date:9/10/2007

art 1 is to explore the effect of food on the pharmacokinetics of

R7128. Preliminary data from the single ascending dose portion of the

study indicate:

-- All doses of R7128 studied were generally safe and well-tolerated.

-- All patients completed the study, and none experienced

gastrointestinal adverse events or serious adverse events during

the study.

-- No hematological or laboratory abnormalities of clinical

significance were noted.

- Part 2 is a multiple ascending dose study of R7128 conducted in 40

patients chronically infected with HCV genotype 1 who have previously

failed interferon therapy. The primary objective of Part 2 is to

assess the safety, tolerability and pharmacokinetics of R7128 after

once-daily or twice-daily dosing for 14 days. The secondary objective

is to assess antiviral activity by measuring the change in HCV RNA.

About Hepatitis C

Hepatitis C is a blood-borne infectious disease of the liver and is a leading cause of chronic liver disease and liver transplants. The World Health Organization estimates that nearly 180 million people worldwide, or approximately 3% of the world's population, are infected with hepatitis C virus (HCV). The CDC has reported that almost four million people in the United States have been infected with HCV, of whom 2.7 million are chronically infected.

Contact

Alan Roemer, Vice President

Investor Relations & Corporate Communications

alan.roemer@pharmasset.com

Office: (609) 613-4125

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties, including without
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
2. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
3. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
4. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
5. Gerons Telomerase Inhibitor Cancer Drug Demonstrates Good Pharmacokinetics and Tolerability in Phase I/II Trial
6. Frova Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of Menstrual Migraine
7. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
8. Cipralex demonstrates superiority to duloxetine for acute treatment of depression in new study
9. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
10. Introgens Advexin Demonstrates Clinical Benefit in Inherited Cancer
11. Prostate Cancer: Clinical Study Demonstrates Superior Efficacy of Docetaxel Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 2014   Hospira, Inc. (NYSE: ... and infusion technologies, today announced that the company will ... on Wednesday, Jan. 14, 2015, in San Francisco.  ... at 10:30 a.m. Pacific time on Wednesday, Jan. 14, ... through a live audiocast accessible via the Investor Relations ...
(Date:12/19/2014)... CARDIFF-BY-THE-SEA, Calif. , Dec. 19, ... SRNE ;  Sorrento), an oncology company developing new ... Inc., a privately-held immuno-oncology company developing proprietary Neukoplast ... based therapy, announced today that the companies have ... next generation CAR-TNK™ (pronounced as "Car-Tank") immunotherapies for ...
(Date:12/19/2014)... , Dec. 18, 2014  Sage Analytics ... generation of equipment for the testing of marijuana ... of the new Luminary™ Profiler, the industry,s first ... measurement in a cost-effective, portable unit. ... specific needs of the cannabis industry, the Luminary™ ...
Breaking Medicine Technology:Sorrento and Conkwest Announce Exclusive Global Collaboration 2Sorrento and Conkwest Announce Exclusive Global Collaboration 3Sorrento and Conkwest Announce Exclusive Global Collaboration 4Sorrento and Conkwest Announce Exclusive Global Collaboration 5Sage Analytics Develops Breakthrough System for Potency Testing of Cannabis Products 2
... Aug. 3 Omnicell, Inc ., (Nasdaq: ... system solutions to acute healthcare facilities, today released the new ... The next generation of packaging technology supports bar code medication ... accuracy. Integrated with the latest WorkflowRx software, version 7.0, this ...
... BEIJING , Aug. 3 ... LTUS ) ("Lotus" or the "Company"), ... in the People,s Republic of,China (the "PRC"), ... ingredient ("API") and tablets of R-Bambuterol for use in,clinical ...
Cached Medicine Technology:Omnicell Introduces New Omnicell Packager With WorkflowRx Software for Improved Pharmacy Efficiency 2Omnicell Introduces New Omnicell Packager With WorkflowRx Software for Improved Pharmacy Efficiency 3Omnicell Introduces New Omnicell Packager With WorkflowRx Software for Improved Pharmacy Efficiency 4Lotus Completed R-Bambuterol's Pilot Scale Production for Clinical Trials 2Lotus Completed R-Bambuterol's Pilot Scale Production for Clinical Trials 3
(Date:12/19/2014)... (PRWEB) December 20, 2014 The print ... Home and Business subscription of the Toronto Star, with ... readership of 622,169. The digital component is distributed nationally ... network of top news sites and partner outlets. To ... here . , The publication features an exclusive ...
(Date:12/19/2014)... -- The intestinal bacteria that cause inflammatory bowel disease, ... inherited, researchers report. The findings, published recently in ... efforts to prevent the disease and treat the 1.6 ... added. "The intestinal bacteria, or ,gut microbiome, you ... big impact on your health for the rest of ...
(Date:12/19/2014)... Potentially illness-causing E. coli bacteria were found on nearly ... a new study. Researchers checked cilantro, basil and ... in Los Angeles and Orange counties in California, and ... tested, 24 percent were positive for E. coli. One ... Both types of bacteria can cause sometimes serious ...
(Date:12/19/2014)... 19, 2014 (HealthDay News) -- Dense bunches of bacteria called ... a new study finds. The researchers said these ... colon. The presence of these biofilms may represent an ... way to predict a person,s risk for the disease, the ... stones, these biofilms may coat the mucus layer of cells ...
(Date:12/19/2014)... Older adults who have lost all their teeth have faster ... have at least some of their teeth, a new study ... provide an early warning of increased risk of physical and ... However, the findings don,t prove that tooth loss causes the ... 3,100 participants 60 and older. People with no remaining teeth ...
Breaking Medicine News(10 mins):Health News:Mark DeMontis, Founder of Courage Canada, shares his passion for bringing hockey to those affected by blindness in Mediaplanet’s “Vision and Hearing” campaign 2Health News:Crohn's, Colitis May Have Genetic Underpinnings, Study Finds 2Health News:E. Coli Germs Found on Farmers Market Herbs 2Health News:Could Bacteria Play a Role in Colon Cancer? 2Health News:Loss of Teeth Linked to Physical, Mental Decline in Study 2
... of Public Health has awarded CNN anchor and special ... efforts while reporting on the devastating effects of Hurricane ... with the award at a ceremony at the Bloomberg ... O,Brien has shown the world tragedies of human conflict, ...
... by New Legislation , , ... (UBC) Annette Stemhagen, DrPH, FISPE, and Gerald Faich, MD, ... Summit held in Washington, DC, on October 28 and ... Jane Axelrad, Associate Director for Policy, CDER, FDA; Claudia ...
... group of consumers filed a proposed,nationwide class-action lawsuit earlier ... AG (FRA: BAY), alleging the pharmaceutical giant,skirted FDA requirements ... (Logo: http://www.newscom.com/cgi-bin/prnh/20080317/AQM144LOGO ) , ... that Bayer markets two of its over-the-counter products --,Bayer ...
... Health plans today proposed guaranteed coverage for people with pre-existing ... , , Under the ... market would be required to offer coverage to all applicants ... individuals were required to maintain health insurance. , ...
... How is a Shortage of Primary Care Physicians Affecting the ... the American College of Physicians (ACP) documents the value of ... bibliography based on a literature review of more than 100 ... primary care in providing patients with better outcomes at lower ...
... they can raise long-term health risks, studies say , , ... poor caregiver relationships each increase levels of the stress ... two studies, published in the November/December issue of ... on children in these common situations. , Long-term or ...
Cached Medicine News:Health News:Bloomberg School awards Goodermote Humanitarian Award to Soledad O'Brien 2Health News:United BioSource Scientists, FDA, and Other Industry Leaders Present to Risk Management and Drug Safety Summit 2Health News:United BioSource Scientists, FDA, and Other Industry Leaders Present to Risk Management and Drug Safety Summit 3Health News:Hagens Berman Files Class Action Against Bayer Healthcare Over Misleading Marketing Campaign 2Health News:Hagens Berman Files Class Action Against Bayer Healthcare Over Misleading Marketing Campaign 3Health News:Health Plans Propose Guaranteed Coverage for Pre-Existing Conditions and Individual Coverage Mandate 2Health News:Health Plans Propose Guaranteed Coverage for Pre-Existing Conditions and Individual Coverage Mandate 3Health News:Primary care provides patients with better outcomes at lower cost 2Health News:Child-Care Relationships Tied to Kids' Stress Levels 2Health News:Child-Care Relationships Tied to Kids' Stress Levels 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: